Proliferative and anti-apoptotic activity in myelodysplastic syndomes and acute myeloid leukemia

In the present study, we determine these two indices in maturing BM cells of MDS and AML patients, and show that quantification of these parameters in MDS and AML can have future clinical implications.
Conclusion:
Concluding, the lowered Ki-67 proliferative indices and elevated Bcl-2 anti-apoptotic indices in blast cells and immature lineage-committed cells led to a better understanding of the pathophysiology and progression of MDS and AML, and explained the low chemotherapy response of these patients. The high therapy-related mortality and the high overall mortality of these patients can also be explained by their proliferative and anti-apoptotic activity. These ratio of these two cell biological processes can prove useful for diagnostic and prognostic applications, and prediction therapy response of different combinations of chemo-, immunotherapy and Venetoclax. To correct for background staining by the conjugated primary antibodies, a negative control using FITC-directly conjugated to non-relevant, isotype immunoglobulins was used. To prevent staining abnormalities caused by ageing of the sample, flow cytometry was performed within 24 hours of receival of the femoral heads. To ensure sufficient cells for flow cytometric analyses, a white blood cell count of approximately 20 x 109 cells/L (quantified with Sysmex XN-9000) was used preferentially. The instrument setup was performed according to standard procedures. Verification of the optical alignment and fluidics system of the Navios™ Flow Cytometer was performed using Flow-Check™ Pro Fluorospheres (Beckman Coulter). The compensation for each fluorochrome was established using Flow-Set™ Pro Fluorospheres (Beckman Coulter) and was performed weekly.